NCT04049903View on ClinicalTrials.gov

Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 2, 2019

Primary Completion Date

June 27, 2022

Study Completion Date

December 21, 2022

Conditions
Advanced Solid Tumor
Interventions
DRUG

MP0310

MP0310 will be examined for safety, tolerability, PK, and PD activity in subjects with advanced solid tumors

Trial Locations (3)

31059

Institut Claudius Regaud; Institut Universitaire du Cancer Toulouse Oncopole (IUCT-O), Toulouse

69008

Centre Léon Bérard, Lyon

94805

Institut Gustave Roussy, Villejuif

Sponsors
All Listed Sponsors
lead

Molecular Partners AG

INDUSTRY